Lymphoma is a malignant tumor originating from lymphatic tissues, medically known as malignant lymphoma, or “lymphoma” as it is often referred to. It is one of the ten most common malignant tumors in China, and its incidence rate has increased significantly in recent years. There is 1 new case every 9 minutes worldwide, and the incidence rate is 3.5 people per 100,000. There are 45,000 new cases and more than 20,000 deaths in China every year. In the ranking of malignant tumor incidence, men take the 9th place and women take the 10th place. It is evident that lymphoma is a relatively common malignant disease. Lymphoma is mainly divided into Hodgkin (Hodgkin) lymphoma (HL) and non-Hodgkin lymphoma (NHL). Hodgkin’s lymphoma is usually more limited, such as confined to the neck or lymphatic tissue in the mediastinum of the chest, and metastases from the primary site to the adjacent lymph nodes, and rarely occurs as jumping lymph node metastases; while non-Hodgkin’s lymphoma tends to spread jumpingly, so non-Hodgkin’s lymphoma should be considered as a systemic disease at the early stage of development, and what is usually called lymphoma is non-Hodgkin’s lymphoma. Depending on the origin of the cells, non-Hodgkin’s lymphoma is divided into B-cell and T-cell, with B-cell lymphoma predominating, accounting for more than 80%. The broad definition of non-Hodgkin’s lymphoma also includes acute lymphoblastic leukemia. There are more than 20 different subtypes of B/T-cell non-Hodgkin’s lymphoma, and these subtypes are inert and aggressive according to their biological behavior and clinical manifestations. The treatment options and prognosis of different subtypes are different, so the classification of lymphoma is particularly complex and its treatment is also complicated. It is also this complexity that leads to a lack of understanding among many physicians who are not specialized in lymphoma, so it is recommended that lymphoma patients must be seen by a physician specialized in lymphoma in order to provide accurate diagnosis and targeted treatment.